Zobrazeno 1 - 10
of 1 638
pro vyhledávání: '"chimeric antigen receptor t cells"'
Publikováno v:
陆军军医大学学报, Vol 46, Iss 17, Pp 1959-1968 (2024)
Objective To investigate the feasibility of granzyme B (GB) promoter-controlled ferritin heavy chain (FTH1) reporter gene expression for monitoring the activation status of chimeric antigen receptor T cells (CAR-T) by magnetic resonance imaging (MRI)
Externí odkaz:
https://doaj.org/article/b92548c2f9ce47429828cc255be42a20
Autor:
Saba Maleki, Zahra Esmaeili, Niloofar Seighali, Arman Shafiee, Sara Montazeri Namin, Mohammad Amin Tofighi Zavareh, Sima Shamshiri Khamene, Izat Mohammadkhawajah, Michael Nanna, Azin Alizadeh-asl, Jennifer M.Kwan, Kaveh Hosseini
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-21 (2024)
Abstract Purpose Chimeric antigen receptor (CAR) T-cell therapy is a new revolutionary method for treating refractory or relapsed hematologic malignancies, CAR T-cell therapy has been associated with cytokine release syndrome (CRS) and cardiotoxicity
Externí odkaz:
https://doaj.org/article/a4c063feb7c54dc295c6e1974c2a37cf
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Objective To construct chimeric antigen receptor (CAR)-T cells targeting epithelial cell adhesion molecule (EpCAM) antigen (anti-EpCAM-CAR-T). Methods A third-generation CAR-T cell construct used a single-chain variable fragment derived from
Externí odkaz:
https://doaj.org/article/b4f25a948a394e4385a4b8e4413de673
Autor:
Jianmin Guo, Qiqi Wu, Hongjian Li, Chun Liang, Jinlong Dai, Shuren Zhang, Cailing Dai, Jishuai Zhang, Yuying Wen, Wei Yang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
PurposeBased on the efficacy data from the previous study of B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell injection, we further examined the delayed toxicity for 8 weeks after a single dose of BCMA CAR T-cell injection to o
Externí odkaz:
https://doaj.org/article/c94470036fd449c2b731f4acb07932c3
Autor:
Nahum Puebla-Osorio, Natalie Wall Fowlkes, Hampartsoum B. Barsoumian, Kristina Xega, Gitika Srivastava, Claudia Kettlun-Leyton, Sara Nizzero, Tiffany Voss, Thomas S. Riad, Christina Wong, Ailing Huang, Yun Hu, Joylise Mitchell, Mingee Kim, Zahid Rafiq, Kewen He, Duygu Sezen, Ethan Hsu, Fatemeh Masrorpour, Aurian Maleki, Carola Leuschner, Maria Angelica Cortez, Philipp Oertle, Marko Loparic, Marija Plodinec, Janet L. Markman, James W. Welsh
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionEffective infiltration of chimeric antigen receptor T (CAR-T) cells into solid tumors is critical for achieving a robust antitumor response and improving therapeutic outcomes. While CAR-T cell therapies have succeeded in hematologic malig
Externí odkaz:
https://doaj.org/article/e15d8e28463245d5a2e2e3d70c939f5b
Autor:
Kovac Milena Blaz, Seruga Bostjan
Publikováno v:
Radiology and Oncology, Vol 58, Iss 2, Pp 170-178 (2024)
Various types of immunotherapy (i.e. immune checkpoint inhibitors [ICIs], chimeric antigen receptor [CAR] T-cells and bispecific T-cell engagers [BiTEs]) and antibody drug conjugates (ADCs) have been used increasingly to treat solid cancers, lymphoma
Externí odkaz:
https://doaj.org/article/b1cc3e3d0d114890aa3c517c510bd9fe
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-15 (2024)
Abstract Undeniably, cancer immunotherapies have expanded the spectrum of cancer treatment, however, some patients do not respond to immunotherapies. This scenario is no different for lung cancer, whose two main types, non-small cell lung cancer (NSC
Externí odkaz:
https://doaj.org/article/69bfd3fa7c6a4ad7981fd82e32a8349f
Autor:
Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R. Chong, Eugenio Fardella, Elise A. Chong, Giulia Gabrielli, Sunita D. Nasta, Daniel J. Landsburg, Jordan Carter, Raymone Pajarillo, Stefan K. Barta, Griffin White, Elizabeth Weber, Ellen Napier, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Marco Ruella
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-5 (2024)
Abstract Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CA
Externí odkaz:
https://doaj.org/article/7841086f48d141fcacd16214fbafb379
The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment
Autor:
Qinghui Xiong, Haiying Wang, Qiushuang Shen, Yan Wang, Xiujie Yuan, Guangyao Lin, Pengfei Jiang
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract In this study, we investigated CD70 as a promising target for renal cell carcinoma (RCC) therapy and developed a potent chimeric antigen receptor T (CAR-T) cells for potential clinical testing. CD70, found to be highly expressed in RCC tumor
Externí odkaz:
https://doaj.org/article/032b207c4faf437da325568ff4a7d0bd
Autor:
Claire Johns, Courtney Erickson, Ashley Jacobs, Jennifer Moon, Christina Baggott, Regina Dagher, Helen Nadel, Jay Balagtas, Catherine Aftandilian, Sneha Ramakrishna, Norman Lacayo, Kara L. Davis, Elliot Stieglitz, Liora Schultz
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Standard testing for disease evaluation in B-cell acute lymphoblastic leukemia (B-ALL) includes examination of the bone marrow and cerebrospinal fluid. Radiographic or functional imaging are indicated when clinical signs of non-CNS extramedullary dis
Externí odkaz:
https://doaj.org/article/804f63d9ff31435e95f8f42657723ec2